New clinical classification and the criteria for predicting long-term outcome in primary biliary cirrhosis

In order to establish a clinical classification and a criteria for predicting long-term outcome In主要biliary cirrhosis (PBC), we studied the autoantibodies （anti-gp210, anti-centromere）HLA-DRB1 and SNPs of various molecules concerning immune-regulation and bile acid metabolism.HLA-DRB1*0803 and CTLA4 SNPs confer susceptibility to PBC development. Positive anti-gp210 andanti-centromere antibodies as well as HLA-DRB1*1502 and *0901 are risk factors for the progressionto liver cirrhosis or portal hypertensionwhile positive anti-gp210 antibodies as as SNPs of MDR3 and integrin V are associated withprogression to hepatic failure.自positive anti-gp210 antibodies是一个强大的风险因素jaundice-type progression (OR>30)，the treatment for PBC became possible with monitoring anti-gp210 antibodies as a serologicalbiomarker. Furthermore, our proposal of PBC progression，anti-gp210 type progression and anti-centromere type progressionsupported by the level of genetic polymorphisms。

In order to establish a clinical classification and a criteria for predicting long-term outcome in primary biliary cirrhosis (PBC), we studied the autoantibodies (anti-gp210, anti-centromere), HLA-DRB1 and SNPs of various molecules concerning immune-regulation and bile acid metabolism. HLA-DRB1*0803 and CTLA4 SNPs confer susceptibility to PBC development. Positive anti-gp210 and anti-centromere antibodies as well as HLA-DRB1*1502 and *0901 are risk factors for the progression to liver cirrhosis or portal hypertension, while positive anti-gp210 antibodies as well as SNPs of MDR3 and integrin ・V are associated with progression to hepatic failure. Since positive anti-gp210 antibodies is a strong risk factor for jaundice-type progression (OR>30), the treatment for PBC became possible with monitoring anti-gp210 antibodies as a serological biomarker. Furthermore, our proposal of PBC progression, anti-gp210 type progression and anti-centromere type progression, was supported by the level of genetic polymorphisms.